Table 1.
Subunit | Species | Cell line/tissue | Type of cell line | Type of deficiency | Viability | Reference(s) |
---|---|---|---|---|---|---|
Ku70 | Human | RERF-LC-A1 | Immortal | Knockdown | Viable | [58] |
Nalm-6 | Immortal | Heterozygous | Viable | [59] | ||
HCT116 | Immortal | Heterozygous | Viable | [60] | ||
Knockout | Inviable | |||||
HAP1 | Immortal | Knockout | Inviable | [8] | ||
KBM7 | ||||||
Mouse | Mouse Embryonic Fibroblasts (MEFs) | Immortal | Knockout | Viable | [61] | |
Embryonic Stem (ES) cells | Primary | Heterozygous | Viable | [16] | ||
Knockout | ||||||
Fibroblasts | Primary | Heterozygous | Viable | [62] | ||
Knockout | ||||||
B and T lymphocytes, thymocytes, MEFs, spleen, bone marrow | Primary | Knockout | Viable | [63] | ||
Ku80 | Hamster | sxi-2, sxi-3 | Immortal | Knockout | Viable | [64] |
CHO-xrs-6 or xrs6a | Immortal | Knockout | Viable | [65, 66] | ||
CHO-xrs-4 or xrs4a | ||||||
CHO-xrs-5 or xrs5a | Immortal | Knockdown | Viable | [66] | ||
XR-V15B | Immortal | Knockout | Viable | [67] | ||
XR-V9B | Immortal | Knockout | Viable | [68] | ||
Human | MRC5V1 | Immortal | Knockdown | Viable | [69] | |
HCT116 | Immortal | Heterozygous | Viable | [7] | ||
Knockout | Inviable | |||||
HeLa | Immortal | Knockdown | Reduced viability | [70] | ||
U2OS | ||||||
SAOS | ||||||
Nalm-6 | Immortal | Heterozygous | Viable | [59] | ||
Mouse | MEFs | Immortal | Knockout | Viable | [6] | |
Bone marrow, B and T lymphocytes, MEFs, spleen | Primary | Knockout | Viable | [6, 71] | ||
ES cells, fibroblasts, thymus | Primary | Knockout | Viable | [6] | ||
Thymocytes | Primary | Knockout | Viable | [71] |
axrs hamster cell lines can be reverted to wild-type levels of Ku80 with azacytidine treatment suggesting they may not be true knockouts, but instead contain one silenced, but functional allele [66]